11:09 AM EDT, 10/14/2025 (MT Newswires) -- Allogene Therapeutics ( ALLO ) said Tuesday that Factor Bioscience's patent infringement lawsuit against its gene-editing technology licensor, Cellectis, could heighten risks related to delays in product discovery, development, and commercialization efforts.

The company said it is "heavily reliant" on its partners for access to Cellectis's Talen gene-editing technology used in its oncology product candidates, and that any inability to use this technology could materially limit its revenue opportunities.

Factor Bioscience filed the lawsuit in the US District Court for the District of Delaware on Sept. 26 against Cellectis and its affiliate Cellectis, alleging that Cellectis's Talen-based technology infringes three of Factor's US patents, according to a regulatory filing.

The complaint also named AstraZeneca ( AZN ) and certain affiliates as defendants, alleging direct infringement by using Cellectis's Talen technology. Allogene said Factor may also choose to assert direct claims against it as a commercial user of the disputed technology.

Shares of Allogene Therapeutics ( ALLO ) were down 3.5% in recent trading.

Price: 1.23, Change: -0.04, Percent Change: -3.46